Lennox-Gastaut syndrome (LGS) is a severe form of childhood epilepsy that is defined by generalized multiple type seizures, slowness of intellectual growth, and a specific EEG disturbance. Children affected might previously have infantile spasms or underlying brain disorder but etiology can be idiopathic.
A six year old boy with normal premorbid development was brought for evaluation of seizure occurring since the age of 18 months. Initially he used to have generalized tonic clonic convulsion, several episodes in a day; however over a period of fi ve years he developed multiple types of seizure: myoclonic jerks, drop attacks and absence seizures. He had been treated without success with multiple anti-epileptic drugs including phenobarbitone, phenytoin, carbamazepine and valproate. At the time of presentation, he was having 7-8 episodes of seizure a day and was on valproate 25mg/kg, carbamazepine 6mg/kg and clonazepam 0.08 mg/kg.
Detailed history revealed that he was born fullterm at hospital. Antenatal, perinatal and postnatal history was insignifi cant. On examination, there was no dysmorphism. His head circumference was 52cm. There was multiple scar over his scalp but there were no neurocutaneous markers. During examination, he had several absence seizures. Rest of the general and systemic examinations were also normal except that he had a stooping gait with short steps. He used to utter few obscene words. His vision and hearing were also normal.
Investigations revealed normal fundus, a normal MRI brain and baseline metabolic profi le. EEG showed sharp slow waves (Fig 1) . He was diagnosed as LGS as he met the three most important criterions for diagnosis which included multiple types of generalized seizures, which are diffi cult to control, slowness of intellectual growth and specifi c EEG fi ndings.
The dose of valproate was increased to 45mg/kg and clonazepam to 0.15mg/kg. Carbamazepine was stopped. The seizure was controlled at the time of discharge.
Discussion
LGS is one of the catastrophic childhood epilepsies. It is defi ned by a triad of symptoms: Multiple types of generaslized seizures, which are diffi cult to control; slowness of intellectual growth often accompanied by mental retardation and behavioural problems and 
Prevalence
LGS accounts for 1-4% of patients with childhood epilepsy. The prevalence of LGS in Atlanta, Georgia, was reported as 0.26 per 1000 live births. Epidemiologic studies in the western or industrialized world (Israel, Spain, Estonia, Italy, Finland) demonstrated that the proportion of patients with LGS seems relatively consistent across the populations studied and similar to that in the United States 8 . There is no such studies carried out in this part but a study done in AIIMS, India by V Karla et al has shown that 3.5% of the children attending neurology clinic were suffering from epileptic encephalopathy including LGS 9 .
The mean age onset of seizure is 26-28 months (range, 1 d to 14 y). The peak age at epilepsy onset is older in patients with LGS of an identifi able etiology than in those whose LGS has no identifi able etiology. They rarely start after the age of eight 2, 3 .
Etiology
In about one third of the affected children cause cannot be identifi ed. These cases are referred to as cryptogenic LGS 2, 3 . On the other side, many of the children who develop LGS had a pre-existing brain disorder or injury. Causes identifi ed include tuberous sclerosis, congenital infections, hereditary metabolic diseases, brain malformation, and brain damage (due to birth asphyxia or other birth injuries, encephalitis, meningitis or head injuries). In a study of childhood recurrent seizures in Red Cross memorial hospital in Cape Town, South Africa, 11% suffered from menigities or encephalitis as a precipitating factor and 55% were intellectually handicapped 10 .
Clinical features
Typically, daily multiple seizure types occur in LGS. Of them, tonic seizures occur more frequently and are often nocturnal. Children may have atonic, myoclonic, partial, tonic-clonic or absence seizures. Additionally, about 60% of children may have status epilepticus 13 . Most children with the Lennox-Gastaut syndrome have intellectual impairment and learning disability that ranges from mild to severe. Behavioral problems and depression are also common, which can be attributed to the brain injury, the frequent seizures, and the lack of normal social stimulation or as side effects of AntiEpilepticDrugs (AEDs) 5, 11 . These children are also more likely to have cerebral palsy, progressive decline in IQ and progressive gait disturbances 5 . They may look irritable, tired or bored. Many children fail to cope with school and need institutional care. The child's development is rarely normal. The seizures can cause sudden falls and/or loss of balance, and patients are advised to wear a helmet to prevent head, face and teeth injury.
The diagnosis of LGS thus depends on the clinical manifestation and typical EEG fi nding characterized by an interictal EEG disturbance of slow spike-wave pattern (< 2.5 Hz), often accompanied by a burst of fast rhythms of 10 to 12 Hz at night [1] [2] [3] .
Treatment
The optimum treatment for Lennox-Gastaut syndrome has yet to be established 12 . Pharmacological treatment consists mainly of one or multiple antiepileptic drugs (AED's). No single treatment regimen could be considered superior to the others, and management depends on the response of the patients. Medical treatment usually starts with valproates followed by adjunctive therapy with either lamotrigine or topiramate 13, 14 .
Most epileptologists have viewed valproate as a fi rst-line drug for LGS since the early 1980's because of: (1) VPA's effi cacy against partial seizures and generalized seizures (including absence); (2) lack of exacerbation of any of the seizure types associated with LGS; (3) relative lack of sedative side-effects compared to barbiturates, and (4) relative ease of use compared to the ketogenic diet.
In cases of intractable seizures surgical treatments like vagus nerve stimulation, corpus callosotomy and Electrical stimulation of the centromedian thalamic nucleus are reported to be effective in few cases.
Ketogenic diet is a reportedly effective option for treatment. A ketogenic diet is a high fat, low protein, low carbohydrates diet that induces ketosis, a state in which there is an excessive amount of ketones in the body. It is very effective and is becoming increasingly popular for treatment of LGS.
Goals and Treatment Objectives
Counseling of the parents or caregiver regarding the nature of the disease is the important part of the treatment. Children with LGS never become seizure free and the goal is to limit the number of seizures while maintaining alertness. The seizures that result in falls and injuries and the atypical absence seizures (that exacerbate the epileptic encephalopathy) should be the primary therapeutic target. Limiting the doserelated sedative and cognitive side effects may improve quality of life for the patient and lastly relative remissions and exacerbations of seizure frequency that are often unrelated to any obvious external factors; quick decisions that lead to discontinuing a drug or adding an additional drug may be regreted later. For clusters of seizures benzodiazepines (rectal diazepam or sublingual/oral lorazepam) can be used.
Prognosis
The long term outcome is poor in terms of seizure control and intellectual development. Catastrophic disorders such as LGS are associated with morbidity and mortality 1 . Eighty percent of patients with LennoxGastaut syndrome continue to have seizures throughout childhood and into their adult life. The mortality rate ranges from 3 to 7% 2 .
